Atrium Therapeutics Hits Cardiology Milestone in Bristol Myers Squibb Partnership

Atrium Therapeutics, Inc. (RNA) announced on Thursday that it has earned a $15 million milestone payment from Bristol Myers Squibb Co. (BMY). The payment follows the successful delivery of a development candidate for a cardiology-targeted compound, marking a key achievement in the companies' ongoing collaboration. This milestone is part of a comprehensive global licensing and research agreement centered on the development of RNA-based therapies for cardiovascular diseases. The partnership leverages Atrium's specialized delivery platform to identify and develop high-quality candidates for cardiology applications. Financially, the current payment represents a small portion of the total potential value of the agreement. Under the terms of the deal, Atrium is eligible to receive up to approximately $1.35 billion in research and development milestone payments and up to $825 million in commercial milestone payments, in addition to tiered royalties on future net sales. Bristol Myers Squibb will assume the financial responsibility for all subsequent clinical development, regulatory filings, and commercialization activities. Atrium CEO Kathleen Gallagher noted that the milestone validates the company's RNA delivery platform and its ability to generate viable cardiology candidates. Atrium shares closed at $13.66 on Wednesday, reflecting a modest increase of 0.96%.